Literature DB >> 8356214

Aldose reductase inhibitors: recent developments.

R Sarges1, P J Oates.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8356214     DOI： 10.1007/978-3-0348-7147-1_5

Source DB:  PubMed          Journal:  Prog Drug Res        ISSN： 0071-786X


× No keyword cloud information.
  11 in total

1.  Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-).

Authors:  S Kaleem Ahmed; Jean-Louis G Etoga; Sarjubhai A Patel; Richard J Bridges; Charles M Thompson
Journal:  Bioorg Med Chem Lett       Date:  2011-05-14       Impact factor: 2.823

2.  Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.

Authors:  D K Wilson; I Tarle; J M Petrash; F A Quiocho
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

3.  Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies.

Authors:  H Rogniaux; A Van Dorsselaer; P Barth; J F Biellmann; J Barbanton; M van Zandt; B Chevrier; E Howard; A Mitschler; N Potier; L Urzhumtseva; D Moras; A Podjarny
Journal:  J Am Soc Mass Spectrom       Date:  1999-07       Impact factor: 3.109

Review 4.  Aldose reductase, oxidative stress and diabetic cardiovascular complications.

Authors:  Srinivasan Vedantham; Radha Ananthakrishnan; Ann Marie Schmidt; Ravichandran Ramasamy
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2012-09

Review 5.  Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.

Authors:  Ravichandran Ramasamy; Ira J Goldberg
Journal:  Circ Res       Date:  2010-05-14       Impact factor: 17.367

6.  Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.

Authors:  H G Forster; P M ter Wee; T C Hohman; M Epstein
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

Review 7.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

8.  Three-dimensional quantitative structure-activity relationships and docking studies of some structurally diverse flavonoids and design of new aldose reductase inhibitors.

Authors:  Utpal Chandra De; Tanusree Debnath; Debanjan Sen; Sudhan Debnath
Journal:  J Adv Pharm Technol Res       Date:  2015 Jan-Mar

Review 9.  Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.

Authors:  Sravya Jannapureddy; Mira Sharma; Gautham Yepuri; Ann Marie Schmidt; Ravichandran Ramasamy
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-11       Impact factor: 5.555

Review 10.  The Bucherer-Bergs Multicomponent Synthesis of Hydantoins-Excellence in Simplicity.

Authors:  Martin Kalník; Peter Gabko; Maroš Bella; Miroslav Koóš
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.